{"entity":{"id":"nct06980532","kind":"trial","name":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer","aka":[],"tldr":"A phase 1/2 trial of fruquintinib in colorectal cancer, run by Liu Huang, now recruiting.","summary":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer is a phase 1/2, interventional study registered as NCT06980532 by Liu Huang, with a registry enrolment figure of 42 participants, started 2025-04-25 and due to reach its primary completion in 2028-12-30. Interventions recorded: Glumetinib Combined with Fruquintinib. Conditions listed: Metastatic Colorectal Cancer. Primary outcome: Recommended dose for Phase II; Objective response rate(ORR). Colorectal eligibility wording from the registry: \"Patients with unresectable metastatic colorectal cancer with microsatellite stable (MSS) confirmed by pathology or histology;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06980532","url":"https://clinicaltrials.gov/study/NCT06980532"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["antiangiogenic","kinase-inhibitors"],"targets":[],"drugs":["fruquintinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06980532","phase":"1/2","setting":"Glumetinib Combined With Fruquintinib in the Treatment of MET Amplification or Protein Overexpression in Third-Line Unresectable Metastatic Colorectal Cancer: A Prospective, Exploratory, Open-Label Clinical Study","sponsor":"Liu Huang","enrolled":42,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06980532/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"fruquintinib","kind":"drug","name":"Fruquintinib","route":"/drugs/fruquintinib/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}